Use of RIT-Seq to Decode Antitrypanosomal Drug Efficacy and Resistance
Alsford, Eckert et al., Nature
A team led by investigators at the London School of Hygiene and Tropical Medicine this week reports its use of all five current human African trypanosomiasis drugs in a genome-scale RNA interference target sequencing screen in Trypanosoma brucei, which it says revealed the "transporters, organelles, enzymes and metabolic pathways that function to facilitate antitrypanosomal drug action." Taking this RIT-seq profiling approach, the team identified "both known drug importers and the only known pro-drug activator, and [linked] more than fifty additional genes to drug action," it writes.
Waters Posts 8 Percent Jump in Q4 Revenues, Notes Growing Interest in Clinical Mass Spec
January 24, 2012
Citing Disappointing Discovery Efforts, Researchers Look to Proteomics' Clinical Future
January 20, 2012
New Instruments, Applications Powering Rise of MALDI-MS as Clinical Proteomics Platform
January 20, 2012
Baylor, Georgia Tech Teams Collaborating on Protein, Metabolite Markers for Ovarian Cancer
January 20, 2012
Proteomics Inches into Food Safety Applications, Offering New Opportunities for Mass Spec Vendors
January 13, 2012
Agilent Partners with Integrated Diagnostics, Further Signaling Focus on MRM-MS as Clinical Platform
January 13, 2012
At JP Morgan, Vendors Tout Strong Mass Spec Releases as Antidotes to Academic/Government Gloom
January 13, 2012
Columbia Team IDs Two Protein Markers to Improve Prediction of Acute Kidney Injury, Adverse Effects
January 13, 2012